Skip to content
Subscriber Only

Narcan Maker Adapt to Be Acquired by Emergent BioSolutions

  • Opioid-overdose antidote used by law enforcement during crisis
  • $735 million deal includes upfront payment of $635 million
Narcan (Naloxone) nasal spray.

Narcan (Naloxone) nasal spray.

Photographer: Drew Angerer/Getty Images 

The maker of Narcan, the opioid-overdose antidote that’s been widely used across the U.S. to combat the nation’s addiction crisis, will be acquired by Emergent BioSolutions Inc.

Emergent said the $735 million deal for Adapt Pharma, which includes a $635 million upfront payment and as much as $100 million in potential sales-based milestones, will expand the use of the nasal spray while maintaining its affordability and raising awareness of naloxone, the generic name for Narcan. The deal is expected to generate annual revenue of as much as $220 million in 2019, the company said.